The year 2017 is one of the deadliest flu season for the past two decades. As we enter another flu season, the need for fast and accurate flu testing is more important than ever. Getting a speedy diagnosis and starting treatment within 48 hours can help you bounce back faster. Here’s Dr. Douglas L. Ambler and Dr. Norman Moore with some tips for navigating this flu season.
Author: healthprofessionalradio
Get Screened for Cervical Cancer
Dr. Maria B. Schiavone (gynecologic oncologist) and Deyka Torres (cervical cancer survivor) bring awareness to encourage all to get screened for cancer and the importance of early detection.
FDA Approval of Gamifant® (emapalumab-Iszg) for Primary HLH Treatment
Dr. Carol Satler discusses the recent (Nov 2018) FDA approval of Gamifant® (emapalumab-lzsg), the first and only treatment indicated for primary hemophagocytic lymphohistiocytosis (HLH). Gamifant®is a product of Sobi, an international bio-pharmaceutical company dedicated to rare diseases.
Updox CRM : Digital Patient Engagement
CEO of Updox CRM, Michael Morgan discusses why healthcare providers have to offer consumers a choice beyond portals, why a secure SMS text solution better reaches patients where they are – on their mobile phones (without the need for an app), and how providers can stop playing phone tag and better engage patients with HIPAA-compliant texting for appointments, scheduling, treatment and more.
Ocugen, Inc. and its Mission to Develop Innovative Therapies to Address Underserved Eye Diseases
Dr. Shankar Musunuri, Ph.D., MBA, is Chairman of the Board, CEO and Co-founder of Ocugen, Inc., discusses the Company’s lead clinical candidate (OCU300) that is currently in Phase 3 for patients with ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, and the Company’s second lead candidate (OCU310) which is also in Phase 3 for patients with dry eye disease.
Antimicrobial Treatments for Infections
CEO of Neem Biotech, Dr. Graham Dixon discusses the presentations at the American Society for Microbiology (ASM) Conference on Biofilms and the North American Cystic Fibrosis (NACF) Conference on a new way to enhance antibiotic effectiveness by reducing biofilms and bacterial virulence more broadly for the development of novel antimicrobial treatments for infections in chronic wounds and chronic respiratory infections including cystic fibrosis.
Holiday Support for People with Multiple Sclerosis (MS)
To build awareness for what the holidays can be like for people with chronic diseases (like MS), Erin Boyt talked about the unique challenges the season can bring.
Erin is a 43-year-old woman who was diagnosed with MS at age 27; she is heavily involved in the development of GatherMS in her local community (Atlanta, GA) and is passionate about patient education and resources; she volunteers at her local MS center to help support and inform other patients who are newly diagnosed.
EHR Interoperability Solutions
Elizabeth Buckle discusses the interoperability questions healthcare organizations should ask before choosing a new EHR for 2019. Recently, Deloitte surveyed 624 primary care and specialty physicians on their attitudes toward EHRs and found that interoperability is their top concern with 62 percent of those surveyed saying they’d like their current system to be more interoperable.
Parkinson’s Foundation Caregiver Support Summit
Parkinsons Foundation Caregiver Summit : Returning guest John L. Lehr discusses the commitment and efforts of the Parkinson’s Foundation in advancing training of neurologists who specialize in Parkinson’s Disease (PD).
Sienna Biopharmaceuticals – Innovation in Medical Dermatology and Aesthetics
Dr. Frederick Beddingfield, Founder, President and Chief Executive Officer of Sienna Biopharmaceuticals, a clinical-stage medical dermatology and aesthetics company, talks about the company’s focus on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Dr. Beddingfield tells a compelling story about Sienna and also discusses the clinical trials the company has underway.